NZ714558A - Formulation comprising a hypolipidemic agent - Google Patents

Formulation comprising a hypolipidemic agent

Info

Publication number
NZ714558A
NZ714558A NZ714558A NZ71455814A NZ714558A NZ 714558 A NZ714558 A NZ 714558A NZ 714558 A NZ714558 A NZ 714558A NZ 71455814 A NZ71455814 A NZ 71455814A NZ 714558 A NZ714558 A NZ 714558A
Authority
NZ
New Zealand
Prior art keywords
formula
formulation
hypolipidemic agent
compounds
present
Prior art date
Application number
NZ714558A
Other languages
English (en)
Inventor
Jitendre D Patel
Prakash Davadra
Snehal Patel
Shafiq Sheikh
Original Assignee
Cadila Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cadila Healthcare Ltd filed Critical Cadila Healthcare Ltd
Publication of NZ714558A publication Critical patent/NZ714558A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
NZ714558A 2013-07-25 2014-07-24 Formulation comprising a hypolipidemic agent NZ714558A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2470MU2013 IN2013MU02470A (OSRAM) 2013-07-25 2013-07-25
PCT/IN2014/000489 WO2015011730A1 (en) 2013-07-25 2014-07-24 Formulation comprising a hypolipidemic agent

Publications (1)

Publication Number Publication Date
NZ714558A true NZ714558A (en) 2017-02-24

Family

ID=51787141

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ714558A NZ714558A (en) 2013-07-25 2014-07-24 Formulation comprising a hypolipidemic agent

Country Status (21)

Country Link
US (2) US9610277B2 (OSRAM)
EP (1) EP3024446A1 (OSRAM)
JP (1) JP2016523895A (OSRAM)
KR (1) KR101786843B1 (OSRAM)
CN (1) CN105407873A (OSRAM)
AP (1) AP2015008876A0 (OSRAM)
AR (1) AR097067A1 (OSRAM)
AU (1) AU2014294548B2 (OSRAM)
BR (1) BR112015031878A2 (OSRAM)
CA (1) CA2917923A1 (OSRAM)
EA (1) EA201690072A1 (OSRAM)
HK (1) HK1219222A1 (OSRAM)
IN (1) IN2013MU02470A (OSRAM)
MA (1) MA38865A1 (OSRAM)
MX (1) MX374628B (OSRAM)
NZ (1) NZ714558A (OSRAM)
PH (1) PH12015502802A1 (OSRAM)
SG (1) SG11201509798PA (OSRAM)
TW (1) TW201545773A (OSRAM)
WO (1) WO2015011730A1 (OSRAM)
ZA (1) ZA201508682B (OSRAM)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007136290A1 (en) 2006-05-23 2007-11-29 Intel Corporation Millimeter-wave communication system with directional antenna and one or more millimeter-wave reflectors
MY191100A (en) 2011-01-31 2022-05-30 Cadila Healthcare Ltd Treatment for lipodystrophy
KR101617812B1 (ko) 2013-04-22 2016-05-03 카딜라 핼쓰캐어 리미티드 비알콜성 지방간 질환을 위한 신규 조성물
PH12015502667B1 (en) 2013-05-30 2023-10-18 Zydus Lifesciences Ltd A process for preparation of pyrroles having hypolipidemic hypocholesteremic activities
TW201636015A (zh) 2013-07-05 2016-10-16 卡地拉保健有限公司 協同性組成物
IN2013MU02470A (OSRAM) 2013-07-25 2015-06-26 Cadila Healthcare Ltd
IN2013MU02905A (OSRAM) 2013-09-06 2015-07-03 Cadila Healthcare Ltd
WO2017064635A2 (en) 2015-10-14 2017-04-20 Cadila Healthcare Limited Pyrrole compound, compositions and process for preparation thereof
KR101913830B1 (ko) * 2016-12-05 2018-10-31 주식회사 코쿤디자인 기능성 led 어셈블리를 이용한 디스플레이 장치
WO2018104916A1 (en) 2016-12-09 2018-06-14 Cadila Healthcare Limited Treatment for primary biliary cholangitis
WO2020165782A1 (en) * 2019-02-13 2020-08-20 Cadila Healthcare Limited Treatment for polycystic ovarian syndrome (pcos)
WO2020183379A1 (en) * 2019-03-11 2020-09-17 Cadila Healthcare Limited Novel salts, crystalline forms and premix of hypolipidemic agent

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4444784A (en) 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
DK149080C (da) 1980-06-06 1986-07-28 Sankyo Co Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre
US5354772A (en) 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
US5030447A (en) * 1988-03-31 1991-07-09 E. R. Squibb & Sons, Inc. Pharmaceutical compositions having good stability
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5089514A (en) 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
WO1994001420A1 (en) 1992-07-03 1994-01-20 Smithkline Beecham Plc Heterocyclic compounds as pharmaceutical
GB9225386D0 (en) 1992-12-04 1993-01-27 Smithkline Beecham Plc Novel compounds
US5387613A (en) 1993-07-23 1995-02-07 Ribogene, Inc. Treatment of tachyarrhythmias of supraventricular origin
GB9326171D0 (en) 1993-12-22 1994-02-23 Smithkline Beecham Plc Novel compounds
BR9508468A (pt) 1994-07-29 1997-11-25 Smithkline Beecham Plc Composto processo para a preparação do mesmo composição farmacéutica processos para o tratamento e/ou profilaxia de hiperglicemia em um mamifero humano ou não humano e para o tratamento de hiperlípidemia hipertensão doença cardiovascular alguns distúrbios de alimentação o tratamento e/ou profilaxia de doença renal a prevenção revers o estabilização ou retardo da progressão de microalbuminuria em um mamifero humano ou não humano uso do composto e composto intermediário
PT826688E (pt) 1995-04-28 2002-02-28 Daiichi Seiyaku Co Composto pentaciclico
GB9600464D0 (en) 1996-01-09 1996-03-13 Smithkline Beecham Plc Novel method
GB9606805D0 (en) 1996-03-30 1996-06-05 Glaxo Wellcome Inc Medicaments
WO1999016758A1 (en) 1997-10-27 1999-04-08 Dr. Reddy's Research Foundation Novel heterocyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
WO1999019313A1 (en) 1997-10-27 1999-04-22 Dr. Reddy's Research Foundation Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them
WO1999008501A2 (en) 1998-04-23 1999-02-25 Dr. Reddy's Research Foundation New heterocyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
NZ504106A (en) 1998-05-27 2003-02-28 Dr Fused Oxazine, Thiazine and pipyridine compounds, process for their preparation and pharmaceutical compositions containing them
JP2002527503A (ja) 1998-10-21 2002-08-27 ノボ ノルディスク アクティーゼルスカブ 新規化合物類、それらの調製及び使用
WO2000023445A1 (en) 1998-10-21 2000-04-27 Novo Nordisk A/S New compounds, their preparation and use
WO2000023451A1 (en) 1998-10-21 2000-04-27 Novo Nordisk A/S New compounds, their preparation and use
CO5150173A1 (es) 1998-12-10 2002-04-29 Novartis Ag Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
DK1250323T3 (da) 2000-01-19 2014-02-03 Cadila Healthcare Ltd Forbindelser med hypolipidemiske og hypokolesterolemiske virkninger, fremgangsmåde til deres fremstilling og farmaceutiske sammensætninger indeholdende dem
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
AU2001286163A1 (en) 2000-09-22 2002-04-02 Dr. Reddy's Research Foundation An improved process for the preparation of 3-aryl-2-hydroxy propanoic acid derivatives
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
US6987123B2 (en) 2001-07-26 2006-01-17 Cadila Healthcare Limited Heterocyclic compounds, their preparation, pharmaceutical compositions containing them and their use in medicine
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
JP4745616B2 (ja) * 2003-02-26 2011-08-10 武田薬品工業株式会社 安定化されたイミダゾール誘導体含有医薬組成物、イミダゾール誘導体の安定化方法
JP4261546B2 (ja) 2003-09-26 2009-04-30 三菱レイヨン株式会社 電気泳動装置および電気泳動法
AU2004318013B8 (en) 2004-03-15 2011-10-06 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
DE602007009489D1 (de) * 2006-02-22 2010-11-11 Eisai R&D Man Co Ltd Stabilisierte pharmazeutische zusammensetzung
WO2007122635A2 (en) 2006-04-26 2007-11-01 Astron Research Limited Controlled release formulation comprising anti-epileptic drugs
JP5424571B2 (ja) * 2007-04-12 2014-02-26 協和発酵キリン株式会社 トピラマート含有固形製剤
EP2504005B1 (en) 2009-11-26 2013-11-06 Genfit Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders
CA2814194A1 (en) * 2010-10-12 2012-04-19 The Johns Hopkins University Antitussive compositions comprising memantine
MY191100A (en) * 2011-01-31 2022-05-30 Cadila Healthcare Ltd Treatment for lipodystrophy
KR101617812B1 (ko) * 2013-04-22 2016-05-03 카딜라 핼쓰캐어 리미티드 비알콜성 지방간 질환을 위한 신규 조성물
PH12015502667B1 (en) 2013-05-30 2023-10-18 Zydus Lifesciences Ltd A process for preparation of pyrroles having hypolipidemic hypocholesteremic activities
TW201636015A (zh) 2013-07-05 2016-10-16 卡地拉保健有限公司 協同性組成物
IN2013MU02470A (OSRAM) 2013-07-25 2015-06-26 Cadila Healthcare Ltd
US9951009B2 (en) 2013-08-29 2018-04-24 Cadila Healthcare Limited Polymorphic form of pyrrole derivative and intermediate thereof
IN2013MU02905A (OSRAM) 2013-09-06 2015-07-03 Cadila Healthcare Ltd

Also Published As

Publication number Publication date
CA2917923A1 (en) 2015-01-29
US20160136131A1 (en) 2016-05-19
AR097067A1 (es) 2016-02-17
KR101786843B1 (ko) 2017-10-18
ZA201508682B (en) 2017-03-29
CN105407873A (zh) 2016-03-16
HK1219222A1 (zh) 2017-03-31
BR112015031878A2 (pt) 2017-07-25
EA201690072A1 (ru) 2016-06-30
AP2015008876A0 (en) 2015-11-30
TW201545773A (zh) 2015-12-16
JP2016523895A (ja) 2016-08-12
US9610277B2 (en) 2017-04-04
US10098868B2 (en) 2018-10-16
KR20160013150A (ko) 2016-02-03
US20170266158A1 (en) 2017-09-21
IN2013MU02470A (OSRAM) 2015-06-26
MA38865A1 (fr) 2017-12-29
WO2015011730A1 (en) 2015-01-29
PH12015502802A1 (en) 2016-03-14
SG11201509798PA (en) 2016-02-26
MX374628B (es) 2025-03-06
MX2015016971A (es) 2016-04-25
EP3024446A1 (en) 2016-06-01
AU2014294548B2 (en) 2017-08-10
AU2014294548A1 (en) 2015-12-17

Similar Documents

Publication Publication Date Title
PH12015502802A1 (en) Formulation comprising a hypolipidemic agent
PH12018502747A1 (en) Boronic acid derivatives and therapeutic uses thereof
NZ716840A (en) Combination formulation of two antiviral compounds
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
CA2875877C (en) Syk inhibitors
MX2015008628A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MY176814A (en) Compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis
BR112015021983A2 (pt) compostos heterocíclicos e usos dos mesmos
MX2011010311A (es) Formulaciones farmaceuticas que comprenden derivados de nitrocatecol y metodos para hacer las mismas.
RS53301B (en) TIOACETATE COMPOUNDS, COMPOSITIONS AND USE PROCEDURES
EA201270216A1 (ru) Фармацевтический состав
RS54526B1 (en) USE OF PIRAZOLOSPIROKETONE DERIVATIVES AS ACETYL-COA CARBOXYLASE INHIBITORS
PH12015501752A1 (en) Substituted bisphenyl butanoic phosphonic acid derivatives as nep inhibitors
EA201792071A2 (ru) Производные глутаримидов, их применение, фармацевтическая композиция на их основе, способы их получения
MX390763B (es) Compuestos de tetraciclina
WO2013177534A3 (en) New salicylic acid derivatives, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof
PH12016500577A1 (en) Piperazine derivatives and the use thereof as medicament
WO2014166836A8 (en) Growth hormone compound formulation
IN2013MU02442A (OSRAM)
TN2015000524A1 (en) Pharmaceutical compositions
SA112330437B1 (ar) تركيبات دوائية محتوية على عامل منوم او مخدر وطريقة تحضيرها
TN2013000137A1 (en) Pharmaceutical compositions containing a dgat 1 inhibitor

Legal Events

Date Code Title Description
PSEA Patent sealed
LAPS Patent lapsed